Rosemont Pharmaceuticals to acquire Aytu BioPharma for $2.70 a share in cashNov 16M&AAytu Biopharma, Inc
Aytu reports Q1 fiscal 2027 results amid pending Rosemont acquisitionNov 16Quarterly updateAytu Biopharma, Incgepirone
Aytu reports first full launch quarter for EXXUA, fiscal 2026 resultsSep 22Quarterly updateAytu Biopharma, Incgepirone